HWP
PCVX icon

Highline Wealth Partners’s Vaxcyte PCVX Stock Holding History

Highline Wealth Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56
Closed -$2.12K – 1034
2025
Q1 		$2.12K Buy
+56
New +$4.48K ﹤0.01% 622

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Highline Wealth Partners's PCVX Position: Q2 2025 in Review

Highline Wealth Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 56 shares — an estimated $2.12K sold.

Highline Wealth Partners first reported a position in PCVX in Q1 2025 and held it in 1 quarter. The position peaked at $2.12K in Q1 2025. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Highline Wealth Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Highline Wealth Partners sold 56 Vaxcyte shares in Q2 2025, an estimated $2.12K.
  • Highline Wealth Partners first reported a position in Vaxcyte in Q1 2025 and held it in 1 quarter.
  • Highline Wealth Partners's Vaxcyte position peaked at $2.12K in Q1 2025.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.